Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

239
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
239
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

728
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
728
Tissue Transplantation01:24

Tissue Transplantation

794
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
794

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Viewpoint on donor-derived cell-free DNA: context of use and clinical utility are key.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis.

Nature communications·2026
Same author

High Concordance between ddPCR- and NGS-Based Quantification of Donor-Derived Cell-Free DNA Percentage after Kidney Transplantation.

Clinical chemistry·2026
Same author

Improving diagnostic performance of kidney allograft rejection with a model combining relative fraction and absolute copies of donor-derived cell-free DNA-Results from 5 independent cohorts.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Urobiome composition after renal transplantation: an exploratory study.

BMC microbiology·2026
Same author

Prevalence and incidence of dysnatremia in European community-dwelling older adults-a secondary analysis of the DO-HEALTH trial.

European journal of endocrinology·2026

Related Experiment Video

Updated: Dec 20, 2025

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.7K

Donor-Derived Cell-Free DNA Testing in Solid Organ Transplantation: A Value Proposition.

Michael Oellerich1, Robert H Christenson2, Julia Beck3

  • 1Department of Clinical Pharmacology, University Medical Center Goettingen, Goettingen, Germany.

The Journal of Applied Laboratory Medicine
|May 25, 2020
PubMed
Summary

Donor-derived cell-free DNA (dd-cfDNA) offers a promising biomarker for monitoring organ transplant recipients. This method aids in early detection of graft injury and rejection, enabling personalized immunosuppression and potentially improving long-term outcomes.

Keywords:
donor-derived cell-free DNAgraft rejectionliquid biopsyorgan transplantationpersonalized immunosuppressionvalue proposition

More Related Videos

Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model
07:34

Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model

Published on: September 22, 2020

4.3K
Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

15.7K

Related Experiment Videos

Last Updated: Dec 20, 2025

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
11:59

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

7.7K
Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model
07:34

Quantification of Circulating Pig-Specific DNA in the Blood of a Xenotransplantation Model

Published on: September 22, 2020

4.3K
Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model
10:11

Using Quantitative Real-time PCR to Determine Donor Cell Engraftment in a Competitive Murine Bone Marrow Transplantation Model

Published on: March 7, 2013

15.7K

Area of Science:

  • Transplantation immunology
  • Biomarker discovery
  • Molecular diagnostics

Background:

  • Personalized immunosuppression is crucial in organ transplantation to prevent graft loss.
  • Current biomarkers lack efficiency in detecting rejection, asymptomatic injury, and under-immunosuppression.
  • Donor-derived cell-free DNA (dd-cfDNA) offers a novel approach for comprehensive allograft monitoring.

Purpose of the Study:

  • To assess the value proposition of dd-cfDNA testing for various stakeholders in solid organ transplantation.
  • To evaluate the clinical validity, economic implications, and limitations of dd-cfDNA monitoring.
  • To highlight the potential of dd-cfDNA in guiding immunosuppression and preventing immune activation.

Main Methods:

  • Systematic review of over 48 published studies on dd-cfDNA in transplantation.
  • Application of the value proposition framework to analyze clinical evidence.
  • Evaluation of dd-cfDNA's role in graft integrity monitoring and rejection detection.

Main Results:

  • Robust clinical evidence supports dd-cfDNA for monitoring graft integrity and detecting rejection.
  • dd-cfDNA testing is essential for early intervention of transplant injury, potentially improving long-term outcomes.
  • Monitoring dd-cfDNA provides a rapid, reproducible method for detecting graft injuries without protocol biopsies.

Conclusions:

  • dd-cfDNA monitoring facilitates personalized immunosuppression strategies.
  • Early detection of graft injuries via dd-cfDNA allows for timely intervention.
  • dd-cfDNA testing offers significant clinical and economic benefits to all stakeholders in organ transplantation.